Cargando…
Immune-Modulating Effects of Conventional Therapies in Colorectal Cancer
Biological heterogeneity and low inherent immunogenicity are two features that greatly impact therapeutic management and outcome in colorectal cancer. Despite high local control rates, systemic tumor dissemination remains the main cause of treatment failure and stresses the need for new developments...
Autores principales: | Kalanxhi, Erta, Meltzer, Sebastian, Ree, Anne Hansen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464272/ https://www.ncbi.nlm.nih.gov/pubmed/32781554 http://dx.doi.org/10.3390/cancers12082193 |
Ejemplares similares
-
Biomarkers of Treatment Toxicity in Combined-Modality Cancer Therapies with Radiation and Systemic Drugs: Study Design, Multiplex Methods, Molecular Networks
por: Ree, Anne Hansen, et al.
Publicado: (2014) -
Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
por: Kalanxhi, Erta, et al.
Publicado: (2016) -
Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
por: Meltzer, Sebastian, et al.
Publicado: (2016) -
Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
por: Kalanxhi, Erta, et al.
Publicado: (2018) -
Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
por: Meltzer, Sebastian, et al.
Publicado: (2019)